Haemonetics
245 hedge funds and large institutions have $3.58B invested in Haemonetics in 2021 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 89 increasing their positions, 93 reducing their positions, and 42 closing their positions.
6% more capital invested
Capital invested by funds: $3.36B → $3.58B (+$214M)
0.06% more ownership
Funds ownership: 99.49% → 99.55% (+0.06%)
0% less call options, than puts
Call options by funds: $24.2M | Put options by funds: $24.3M
4% less repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 93
5% less funds holding
Funds holding: 258 → 245 (-13)
24% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 42
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| 1 |
BlackRock
New York
|
+$63.8M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
+$35.5M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$34.9M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$32.3M |
| 5 |
RA
Royce & Associates
New York
|
+$24.2M |
Top Sellers
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$97.5M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$36.3M |
| 3 |
Morgan Stanley
New York
|
-$31.1M |
| 4 |
Renaissance Technologies
New York
|
-$29.7M |
| 5 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
-$24.6M |
HAE Hedge Fund Activity: Q3 2021 in Review
245 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q3 2021, worth a combined $3.58B — up 6.4% from $3.36B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of HAE and 32 opened new positions — a net loss of 10 holders — while 93 trimmed existing stakes and 89 added.
The largest buyer was BlackRock, adding an estimated $63.8M. The largest seller was Capital Research Global Investors, cutting an estimated $97.5M.
- 245 institutional investors held Haemonetics (HAE) as of Q3 2021, down from 258 in Q2 2021.
- Funds reported $3.58B of Haemonetics stock for Q3 2021, up 6.4% quarter-over-quarter.
- 32 funds opened new Haemonetics positions in Q3 2021 and 42 closed out, a net change of -10 holders.
- The largest Haemonetics buyer in Q3 2021 was BlackRock, an estimated $63.8M added.
- The largest Haemonetics seller in Q3 2021 was Capital Research Global Investors, an estimated $97.5M sold.
Based on aggregated 13F filings for Q3 2021.